

# Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

---

*Source:* <http://sci.tech-archive.net/Archive/sci.med.cardiology/2007-05/msg00530.html>

---

- *From:* William Wagner <~~not-to-here-williamwag@xxxxxxxx~~>
  - *Date:* Thu, 24 May 2007 11:11:27 -0400
- 

In article <1180016201.137033.126960@xx>, MarilynMann <mannm@xxxxxxxx> wrote:

The Lancet has an editorial on its website discussing the controversy: [http://multimedia.thelancet.com/pdf/rosiglitazone\\_editorial.pdf](http://multimedia.thelancet.com/pdf/rosiglitazone_editorial.pdf). The unsigned editorial suggests that "the FDA, physicians, and patients can reasonably await the results of RECORD, a phase III trial designed specifically to study cardiovascular outcomes."

Asked to comment, Journal Watch Cardiology Editor-in-Chief Harlan M. Krumholz wrote: "Why would you wait when Avandia has never been shown to avert events or save lives? And now that there is evidence of potential harm – and there are alternative meds – it seems to me that the pressure is on the company to show that it is safe and effective."

Marilyn

Just an observation.

But it seems medicine as a business has eclipsed medicine as an art. I find more info first in the Wall Street Journal than any where else besides SMC :)).

So the question becomes what is of import return on investment or the health of the people. I guess this is a call for a more socialized human centered approach for fixing our ill's. Cause and remedies and preventive issues need clarity need a champion.

Bill who wonders if Avandia user's will ever see "Why would you wait when Avandia has never been shown to avert events or save lives? "

--

S Jersey USA Zone 5 Shade

Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

<http://www.ocutech.com/> High tech Vision aid

This article is posted under fair use rules in accordance with Title 17 U.S.C. Section 107, and is strictly for the educational and informative purposes. This material is distributed without profit.

Re: Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes